This is a standard board appointment with no immediate stock-moving catalyst. Grissinger's dealmaking background may signal Lipocine's intent to pursue licensing or partnerships for its pipeline, but no such activity has been announced. Monitor for future partnership or financing news.
Price Chart
Executive Summary
Lipocine appointed Michael J. Grissinger to its Board of Directors, expanding the board to five members. Grissinger brings over 20 years of pharma licensing and M&A experience from Johnson & Johnson, which could support partnership efforts. The filing is a routine board appointment with no financial terms or operational changes disclosed.
Key Facts
- Board expanded to five members and Michael Grissinger appointed as independent director effective August 3, 2026
- Grissinger receives initial stock option grant to purchase 2,000 shares of common stock and an annual retainer of $55,000
- Grissinger spent over 20 years at Johnson & Johnson in senior licensing, corporate development, and M&A roles
- Grissinger currently serves on boards of Aprea Therapeutics (APRE) and Adicet Bio (ACET)
Financial Impact
Nominal — initial option grant for 2,000 shares and $55,000 annual retainer, immaterial relative to market cap
Risk Factors
- No material financial or operational changes from this filing
- Biotech pipeline risk remains: all candidates are preclinical or early-stage, and TLANDO commercialization progress is unclear
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-035762 |
| Exhibit: ex99-1.htm | 0001493152-26-035762 |
| Document: 0001493152-26-035762-index-headers.html | 0001493152-26-035762 |
| Document: 0001493152-26-035762-index.html | 0001493152-26-035762 |
| Document: 0001493152-26-035762.txt | 0001493152-26-035762 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 7d ago | 8-K | $1.62 | awaiting T+60 | — | $1.46 (−10.14%) |
Oct 7, 2026 20d ago | 8-K | $2.20 | awaiting T+60 | — | $1.46 (−33.83%) |
Sep 16, 2026 5w ago | 8-K | $2.22 | awaiting T+60 | — | $1.46 (−34.43%) |
Sep 14, 2026 6w ago | 8-K | $2.22 | awaiting T+60 | — | $1.46 (−34.43%) |
Sep 11, 2026 6w ago | 8-K | $2.27 | awaiting T+60 | — | $1.46 (−35.87%) |
Sep 10, 2026 6w ago | 8-K | $2.25 | awaiting T+60 | — | $1.46 (−35.30%) |
Aug 4, 2026 12w ago | Press Release | $2.13 | awaiting T+60 | — | $1.46 (−31.66%) |
Aug 3, 2026 12w ago | 8-K | $2.11 | awaiting T+60 | — | $1.46 (−31.01%) |
Jun 4, 2026 20w ago | 8-K | $2.21 $2.17 | ▼ −1.81% | ▼ −3.69% | $1.46 (−34.13%) |
May 26, 2026 21w ago | 8-K | $2.28 $2.09 | ▼ −8.33% | ▼ −10.21% | $1.46 (−36.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers